OP
ALXN

Omni Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Omni Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$153M Buy
1,003,383
+836,234
+500% +$129M 7.56% 2
2020
Q4 		$26.1M Buy
+167,149
New +$21.5M 1.53% 14
2015
Q2 		$2.1M Buy
+13,162
New +$2.27M 29.38% 2

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Omni Partners's ALXN Position: Q1 2021 in Review

Omni Partners increased its Alexion Pharmaceuticals (ALXN) stake by 500% in Q1 2021, buying an estimated $129M and bringing the position to 1,003,383 shares worth $153M. The position accounts for 7.56% of the portfolio, ranked #2.

Omni Partners first reported a position in ALXN in Q2 2015 and has held it in 3 quarters since. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Omni Partners held 1,003,383 shares of Alexion Pharmaceuticals worth $153M as of Q1 2021.
  • Omni Partners bought 836,234 Alexion Pharmaceuticals shares in Q1 2021, an estimated $129M.
  • Alexion Pharmaceuticals made up 7.56% of Omni Partners's portfolio in Q1 2021, its #2 holding.
  • Omni Partners first reported a position in Alexion Pharmaceuticals in Q2 2015 and has held it in 3 quarters since.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Omni Partners's 13F filing for Q1 2021, filed 17 May 2021.